|1.||Sekiguchi, Fumiko: 6 articles (02/2015 - 01/2012)|
|2.||Kawabata, Atsufumi: 6 articles (02/2015 - 01/2012)|
|3.||Okawa, Yasumasa: 3 articles (10/2012 - 01/2012)|
|4.||Yoshida, Shigeru: 2 articles (02/2014 - 02/2013)|
|5.||Kanaoka, Daiki: 2 articles (02/2014 - 02/2013)|
|6.||Aoki, Yuka: 2 articles (02/2013 - 07/2012)|
|7.||Tsubota-Matsunami, Maho: 2 articles (02/2013 - 01/2012)|
|8.||Matsunami, Maho: 2 articles (10/2012 - 07/2012)|
|9.||Kawabata, A: 2 articles (08/2011 - 05/2011)|
|10.||Matsunami, M: 2 articles (08/2011 - 05/2011)|
|1.||Neuralgia (Stump Neuralgia)
08/11/2011 - "Together, our study demonstrates the effectiveness of NNC 55-0396 in inhibiting Ca(v)3.2, and then suggests that paclitaxel-evoked neuropathic pain might involve the enhanced activity of T-type calcium channels and/or CSE in rats, but not upregulation of Ca(v)3.2 and CSE at protein levels, differing from the previous evidence for the neuropathic pain model induced by spinal nerve cutting in which Ca(v)3.2 was dramatically upregulated in DRG."
01/01/2012 - "Intracolonic administration of NaHS, an H(2)S donor, evoked visceral pain-like nociceptive behavior and referred hyperalgesia in mice, an effect abolished by NNC 55-0396, a selective T-type Ca(2+)-channel blocker, or by knockdown of Ca(v)3.2. "
01/01/2015 - "Finally, preceding and periodic intraplantar treatment with the T-type calcium channel blockers mibefradil and NNC 55-0396 markedly reduced and reversed mechanical hyperalgesia during the acute and sub-acute phases, respectively, in mice. "
02/28/2014 - "Intraplantar administration of Na2S, like NaHS, caused mechanical hyperalgesia, an effect blocked by NNC 55-0396, a T-channel inhibitor. "
02/01/2013 - "In rats, intraplantar (i.pl.) administration of db-cAMP or PGE(2) caused mechanical hyperalgesia, an effect suppressed by AKAPI, two distinct T-channel blockers, NNC 55-0396 and ethosuximide, or ZnCl(2) , known to inhibit Ca(v) 3.2 among T channels. "
08/11/2011 - "Repeated systemic administration of paclitaxel caused delayed development of mechanical hyperalgesia, which was reversed by single intraplantar administration of NNC 55-0396 or mibefradil, and by silencing of Ca(v)3.2 by antisense oligodeoxynucleotides. "
05/20/2011 - "In contrast to mibefradil, NNC 55-0396 is well tolerated and suppresses tremor, and exerts less cytochrome P450 inhibition. "
05/20/2011 - "In the GABAA α1-null model, NNC 55-0396 but not mibefradil, (each at 20mg/kg), suppressed tremor while NNC 55-0396 at 12.5mg/kg suppressed harmaline-induced tremor by half by 20-100min, whereas mibefradil at the same dose did not significantly affect tremor. "
11/01/2010 - "In addition, ECN and NNC 55-0396 suppressed harmaline tremor as well in Cav3.1-null mice as in wild-type mice. "
05/20/2011 - "Comparison of mibefradil and derivative NNC 55-0396 effects on behavior, cytochrome P450 activity, and tremor in mouse models of essential tremor."
05/01/2015 - "NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction."
03/15/2015 - "Blockade by NNC 55-0396, mibefradil, and nickel of calcium and exocytotic signals in chromaffin cells: implications for the regulation of hypoxia-induced secretion at early life."
|5.||Essential Tremor (Essential Tremors)
|1.||T-Type Calcium Channels (T-Type Calcium Channel)
|4.||sodium bisulfide (NaHS)
|5.||Protein Isoforms (Isoforms)
|7.||Ascorbic Acid (Vitamin C)
|9.||Small Interfering RNA (siRNA)
|10.||Proteins (Proteins, Gene)
|1.||Heterologous Transplantation (Xenotransplantation)